Page 36 - DIAGEN-EN

Hematology primeFISH Products

HEMATOLOGY
PANEL

17-207 DEK-NUP214 t(6;9)

Rearrangements of the NUP214 gene have been identified of the t(6;9)(p22.3;q34.1) translocation and constitutes
in several hematological malignancies, including T-cell a specific subset of AML according to the World Health
acute lymphoblastic leukemia (T-ALL), acute myeloid Organization 2008 classification. The fusion resulting
leukemia (AML), and myelodysplastic syndrome (MDS). from the rearrangement between the DEK gene at 6p22.3
Several fusion partners have been identified for NUP214, and the NUP214 gene at 9q34.12-q34.13, known as t(6;9)
with the most common ones being the chromatin-binding (p22;q34), accounts for 0.5% to 4% of acute myeloid leu-
factor DEK, the histone chaperone SET, and the tyrosine kemia (AML) cases and is associated with poor prognosis.
kinase ABL1. The DEK-NUP214 fusion occurs as a result

TRANSLOCATION

6p22.3

RH40924 RH12676
5' 3'
Tel Cent
DEK
673 kb

RH63154 RH41777 NORMAL
3' 5'
Cent Tel
NUP214
550 kb

TRANSLOCATION
9q34.12-q34.13

(Not to scale)

References
www.diagen.com.tr Fahrenkrog B (2014) New J Sci 2014: Article ID468306, 18 pages.

Takeda A & Yaseen NR (2014) Semin Cancer Biol 27: 3-10.
Wilkinson DG: In Situ Hybridization, A Practical Approach, Oxford University Press (1992) ISBN 0 19 963327 4.
Chi et al, 2008, Arch. Pathol. Lab. Med., 132; 1835-1837.

36 PRODUCT CATALOGUE